Topic: Clinical Trial Results
Viking Therapeutics’ lead lipid disorder asset met its endpoints in a midstage trial, dropping cholesterol and liver fat levels in patients with NAFLD.
The decision comes a year after the monoclonal antibody, GNbAC1, failed to beat placebo in a phase 2b trial.
The data suggest filgotinib is safe and as effective as JAK rivals including AbbVie’s upadacitinib, setting the stage for a four-way commercial scrap.
BMS’ tyrosine kinase 2 inhibitor checked off a phase 2 psoriasis trial, showing high levels of skin clearance after three months of daily treatment.
Celtaxsys’ cystic fibrosis drug cleared phase 2 by reducing lung exacerbations, such as heavy coughing episodes that can lead to irreversible damage.
Athenex’s ointment cleared 100% of precancerous actinic keratosis lesions within 60 days, including in the face and scalp, in two phase 3 trials.
Pluristem and Thermo Fisher will collaborate to scale up manufacturing of regenerative medicines, to build an industry capable of millions of doses.
Biogen and Eisai’s phase 2 Alzheimer’s trial has re-emerged, slowing clinical symptom decline and reducing amyloid plaque accumulation in the brain.
Alzheimer’s startup Cortexyme rounded up $76 million for a potentially first-in-class antibiotic treatment, while others struggle in the field.
Esperion’s phase 3 results of bempedoic acid showed it lowered cholesterol levels, but 13 deaths were also reported, causing shares to slide.